Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: Bayer’s pipeline refresh; J&J’s selective pharma M&A approach; silver lining for Gilead’s Trodelvy miss?; paying for obesity drugs; and the story behind Vertex and CRISPR’s gene therapy breakthrough.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 26 January 2024, including: Bayer’s pipeline refresh; J&J’s selective pharma M&A approach; silver lining for Gilead’s Trodelvy miss?; paying for obesity drugs; and the story behind Vertex and CRISPR’s gene therapy breakthrough.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Bayer’s Pipeline Refresh Focuses On Early Stage Despite Near-Term Growth Needs" - Scrip, 18 Jan, 2024.)
(Also see "J&J Has An Appetite For Pharma M&A, But Knows What It Likes" - Scrip, 23 Jan, 2024.)
(Also see "Do The Dark Clouds Over Gilead’s Trodelvy Have A Silver Lining?" - Scrip, 22 Jan, 2024.)
(Also see "Paying For Obesity Drugs: The Looming Affordability Crisis" - Scrip, 19 Jan, 2024.)
(Also see "CRISPR Therapeutics And Vertex’s CRISPR Breakthrough: How And Why They Got There First" - Scrip, 19 Jan, 2024.)